GATC Will Use 454's GS20 to Sequence DNA and Transcriptomes, and Analyze Mutations | GenomeWeb
NEW YORK (GenomeWeb News) — GATC Biotech will use 454 Life Sciences’ genome sequencing technology for its sequencing and analysis business, GATC said today.
 
GATC, based in Konstanz, Germany, said that by adapting 454’s technology with traditional Sanger technology it can cut the sequencing and analysis time in half and reduce costs.
 
The company also said it will use 454’s instrument to sequence whole transcriptomes and for in-depth analyses of rare mutations.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.